阿那莫林Adlumiz能有效改善癌症恶病质患者的生活质量

The launch of Anamorelin and Adlumiz provides a new treatment option for patients with cancer cachexia and helps improve the quality of life of such patients. Anamorelin Adlumiz is a ghrelin receptor agonist that can be used to treat cancer cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors. It acts on ghrelin receptors. In addition to increasing appetite, it also has anti-inflammatory effects, inhibits muscle protein decomposition, and increases fat accumulation.

Anamorelin Adlumiz was approved in Japan in January 2021. The approval was primarily based on the results of two clinical studies conducted in Japan in patients with cancer cachexia: a multicenter, placebo-controlled, randomized, double-blind, parallel-group study in patients with non-small cell lung cancer (NSCLC) (ONO-7643-04 study); and a multicenter, open-label, uncontrolled Phase III study in patients with colorectal, gastric, and pancreatic cancer (ONO-7643-05 study).

The first of the two studies showed that 63% of patients maintained or gained weight and had an improvement in appetite. The results of the second experiment were that patients in the anamorelin-Adlumiz group gained an average of 1.38 kg in weight, while patients in the placebo group lost an average of 0.17 kg. It can be seen that Anamorelin Adlumiz can relieve patients' pain, improve their quality of life and disease progression, have a positive effect on the patient's condition, and have a significant therapeutic effect.

The above is the introduction about Anamorelin Adlumiz. If patients want to know more about the latest drug information about this drug (such as the price of Anamorelin Adlumiz, purchase method, precautions, usage, etc.), they can contact the medical companion travel service at any time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: